SAFETY ASPECTS AND PHARMACOKINETICS OF INHALED AEROSOLIZED GADOLINIUM

被引：20

作者：

BERTHEZENE, Y ^{[1
]}

MUHLER, A ^{[1
]}

LANG, P ^{[1
]}

SHAMES, DM ^{[1
]}

CLEMENT, O ^{[1
]}

ROSENAU, W ^{[1
]}

KUWATSURU, R ^{[1
]}

BRASCH, RC ^{[1
]}

机构：

[1] UNIV CALIF SAN FRANCISCO,DEPT RADIOL,CONTRAST MED LAB,513 PARNASSUS AVE,SAN FRANCISCO,CA 94143

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1993年 / 3卷 / 01期

关键词：

AEROSOLS; CONTRAST ENHANCEMENT; GADOLINIUM; LUNG; MR; SAFETY;

D O I：

10.1002/jmri.1880030121

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

This study evaluated the pharmacokinetics and potential toxicity of inhaled aerosolized gadopentetate dimeglumine. The pharmacokinetics were evaluated with in vitro relaxometry of the lungs, blood, urine, and liver before and for up to 36 hours after a 5-minute inhalation of aerosolized gadopentetate dimeglumine (0.25 mol/L). For assessment of potential toxicity, hemodynamic variables were monitored during and for 10 minutes after inhalation. Extravascular lung water was measured before and after exposure. Finally, the potential for tissue damage was evaluated histologically. Pulmonary clearance of aerosolized gadopentetate dimeglumine was monoexponential with a half-time of 2.16 hours. Aerosolized gadopentetate dimeglumine was excreted through the kidneys, as shown by the decrease in urinary T1. Renal elimination was completed by 30 hours. No acute hemodynamic effect, histologic change, or induction of edema was demonstrated. This study shows that inhalation of aerosolized gadopentetate dimeglumine is well tolerated in rats and favors the further evaluation of this administration route, including clinical trials.

引用

页码：125 / 130

页数：6

共 21 条

[1]

Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W, Tolerance data of Gd‐DTPA: a review, Eur J Radiol, 13, pp. 15-20, (1991)

[2]

Katayama H., Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K, Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committe on the Safety of Contrast Media, Radiology, 175, pp. 621-628, (1990)

[3]

Berthezene Y, Vexler V, Clement O, Muhler A, Moseley ME, Brasch RC, Contrast‐enhanced MR imaging of the lung: assessments of ventilation and perfusion, Radiology, 183, pp. 667-672, (1992)

[4]

Berman M, Weiss MF, SAAM manual, (1978)

[5]

Berman M, Beltz WF, Greif PC, Chabay R, Boston RC, CONSAM users guide, (1983)

[6]

Pearce ML, Yamashita J, Beazell J, Measurement of pulmonary edema, Circ Res, 16, pp. 482-488, (1965)

[7]

Julien M, Hoeffel JM, Flick MR, Oleic acid lung injury in sheep, J Appl Physiol (1985), 60, pp. 433-440, (1986)

[8]

Isawa T, Wasserman K, Taplin GV, Lung scintigraphy and pulmonary function studies in obstructive airway disease, Am Rev Respir Dis, 102, pp. 161-172, (1970)

[9]

Isitman AT, Manoli R, Schmidt GH, Holmes RA, An assessment of alveolar deposition and pulmonary clearance of radiopharmaceuticals after nebulization, Am J Roent‐genol Radium Ther Nucl Med, 120, pp. 776-781, (1974)

[10]

Alderson PO, Biello DR, Gottschalk A, Et al., Tc‐99m‐DTPA aerosol and radioactive gases compared as adjuncts to perfusion scintigraphy in patients with suspected pulmonary embolism, Radiology, 153, pp. 515-521, (1984)

← 1 2 3 →